Preview

Нервно-мышечные болезни

Расширенный поиск

Злокачественная гипертермия (синдром Икара): новый взгляд на старую проблему


https://doi.org/10.17650/2222-8721-2014-0-1-21-29

Полный текст:

Аннотация

В лекции освещена краткая история изучения вопросов этиологии и патогенеза одного из наиболее драматических осложнений общей анестезии – злокачественной гипертермии (синдрома Икара). Подчеркнута важность междисциплинарного подхода к разработке методов профилактики и лечения этого фармакогенетического состояния в практике невролога и анестезиолога.

Об авторах

Н. А. Шнайдер
Кафедра медицинской генетики и клинической нейрофизиологии Института последипломного образования ГБОУ ВПО «Красноярский государственный университет им. проф. В.Ф. Войно-Ясенецкого»
Россия


В. А. Шнайдер
отделение анестезиологии и реанимации КГБУЗ «Красноярская краевая клиническая больница»
Россия


Список литературы

1. Шнайдер Н.А. Злокачественная гипертермия: генетика, диагностика, профилактика. Острые и неотложные состояния в практике врача 2007;4:32–6.

2. Гринштейн А.Б., Шнайдер Н.А., Шнайдер В.А. Неврологические осложнения общей анестезии — особенности клиники, диагностики и лечения. Метод. рекомендации. Красноярск: КрасГМА, 2000.

3. Baker K.R., Landriscina D., Kartchner H., Mirkes D.M. The Icarus effect: the influenceof diluent warming on dantrolene sodium mixing time. AANA J 2007;75(2):101–6.

4. Brandom B.W. The genetics of malignant hyperthermia. Anesthesiol Clin North America 2005;23(4):615–9.

5. Dinman S. Malignant hyperthermia. Plast Surg Nurs 2006;26(4):206–7.

6. Rosenberg H., Davis M., James D. et al. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21.

7. Denborough M.A., Forster J.F., Lovell R.R. et al. Anaesthetic deaths in a family. British J Anaesth 1962;34:395–6.

8. Glahn K.P. Malignant hyperthermia. Ugeskr Laeger 2003;165(17):1763–8.

9. Шнайдер Н.А., Салмина А.Б. Неврологические осложнения общей анестезии (2-е изд., перераб. и доп.). М.: Медика, 2009. 280 с.

10. Larach M.G., Gronert G.A., Allen G.C. et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010;110(2):498–507.

11. Harrison G.G., Biebuyck J.F., Terblanche J. et al. Hyperpyrexia during anaesthesia. Br Med J 1968;3(5618):594–5.

12. Ohnishi S.T., Katsuoka M. Why does halothane relax cardiac muscle but contract malignant hyperthermic skeletal muscle? Adv Exp Med Biol 1991;301:73–87.

13. Huxley H.E. The mechanism of muscular contraction. Science 1969;164(3886):1356–65.

14. Britt B.A., Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J 1970;17(4):293–315.

15. Ellis F.R., Harriman D.G., Keaney N.P. et al. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971;43(7):721–2.

16. Karan S.M., Lojeski E.W., Haynes D.H. et al. Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. Anesth Analg 1996;82(4):796–802.

17. MacLennan D.H., Phillips M.S. Malignant hyperthermia. Sci 1992;256:789–94.

18. Meola G., Sansone V., Rotondo G. et al. Muscle biopsy and cell cultures: potential diagnos-tic tools in hereditary skeletal muscle channelopathies. Eur J Histochem 2003;47(1):17–28.

19. Ellis K.O., Castellion A.W., Honkomp L.J. et al. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci 1973;62(6):948–51.

20. Harrison G.G. Death attributable to anaesthesia. A 10-year survey (1967–1976). Br J Anaesth 1978;50(10):1041–6.

21. Gronert G.A., Milde J.H., Theye R.A. Dantrolene in porcine malignant hyperthermia. Anesthesiology 1976;44(6):488–95.

22. Kolb M.E., Horne M.L., Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982;56(4):254–62.

23. Picard J., Ward S., Meek T. Antidotes to anesthetic catastrophe: lipid emulsion and dantrolene. Anesth Analg 2007;105(1):283–4.

24. Zhao F., Li P., Chen S.R. et al. Dantrolene inhibition of ryanodine recep-tor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001;276(17):13810–6.

25. Шнайдер Н.А. Злокачественная гипертермия: лечение. Острые и неотложные состояния в практике врача 2007;5:30–3.

26. Rosenberg H., Antognini J..F., Muldoon S. Testing for malignant hyperthermia. Anesth 2002;96:232–7.

27. Ta T.A., Pessah I.N. Ryanodine receptor type 1 (RYR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by noncoplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95). Neurotoxicology 2007;28(4):770–9.

28. Lanner J.T. Ryanodine receptor physiology and its role in disease. Adv Exp Med Biol 2012;740:217–4.

29. Hubner C.A., Jentsch T.J. Ion channel diseases. Hum Mol Gen 2002;11(20):2435–45.

30. Hudson A.J., Ebers G.C., Bulman D.E. The skeletal muscle sodium and chloride channel diseases. Brain 1995;118:547–63.

31. MacLennan D.H., Duff C., Zorzato F. et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990;343(6258): 559–61.

32. McCarthy T.V., Datar S., Mackrill J.J. Activation of ryanodine receptor/Ca2+ release channels downregulates CD38 in the Namalwa B lymphoma. FEBS Lett 2003;554(1-2):133–7.

33. MacLennan D.H., Chen S.R. Store overload-induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes. J Physiol 2009;587(Pt 13):3113–5.

34. Katsuya H., Misumi M., Ohtani Y., Miike T. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiol 1988;68(6):945–8.

35. Zierz S., Schmitt U. Inhibition of carnitine palmitoyltransferase by malonyl-CoA in human muscle is influenced by anesthesia. Anesthesiol 1989;70(2):373.

36. Fiege M., Wappler F., Weisshorn R. et al. In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiol 2003;98(4):944–9.

37. Fruen B.R., Mickelson J.R., Louis C.F. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem 1997;272(43):26965–71.

38. Zhao F., Li P., Chen S.R. et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001;276(17):13810–86.

39. Jurkat R.K., Lerche H., Mitrovic N. et al. Teaching course: ion channelopathies in neurology. J Neurol 1999;46:758–63.

40. Guis S., Figarella-Branger D., Monnier N. et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004;61:106–13.

41. Islander G., Jungner M. Anesthesia in hereditary peripheral muscular disease. Lakartidningen 2005;102(8):566–71.

42. Halsall P.J., Bridges L.R., Ellis F.R., Hopkins P.M. Should patients with central core disease be screened for malignant hyperthermia? J Neurol Neurosurg Psychiatry1996;61:119–21.

43. Jensen V. The anaesthetic management of a patient with Emery-Dreifuss muscular dystrophy. Can J Anaesth 1996;43(9):968–71.

44. Litman R.S., Rosenberg H. Malignant hyperthermia-associated diseases: State of the Art uncertainty. Anesth Analg 2009;109:1004–5.

45. Kim D.C. Malignant hyperthermia. Korean J Anesthesiol 2012;63(5):391–401.

46. Pollock N.A., Langton E.E. Management of malignant hyperthermia susceptible parturients. Anaesth Intensive Care 1997;25(4):398–407.

47. Baker K.R., Landriscina D., Kartchner H., Mirkes D.M. The Icarus effect: the influence of diluent warming on dantrolene sodium mixing time. AANA J 2007;75(2):101–6.

48. Naguib M., Flood P., McArdle J.J., Brenner H.R. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology 2002;(96):202–31.

49. Hirshey Dirksen S.J., Larach M.G., Rosenberg H. et al. Special article: Future directions in malignant hyperthermia research and patient care Anesth Analg 2011;113(5):1108–19.

50. Stowell K.M. Malignant hyperthermia: a pharmacogenetic disorder. Pharmacogenomics 2008;9:1657–72.


Для цитирования:


Шнайдер Н.А., Шнайдер В.А. Злокачественная гипертермия (синдром Икара): новый взгляд на старую проблему. Нервно-мышечные болезни. 2014;(1):21-29. https://doi.org/10.17650/2222-8721-2014-0-1-21-29

For citation:


Shnayder N.A., Shnayder V.A. Malignant hyperthermia (icarus syndrome): new view on the old problem. Neuromuscular Diseases. 2014;(1):21-29. (In Russ.) https://doi.org/10.17650/2222-8721-2014-0-1-21-29

Просмотров: 658


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2222-8721 (Print)
ISSN 2413-0443 (Online)